Evidence map›Paper›PMID 34287925›Full record

ArticleTransfusion2021

Allo-anti-M: Detection peaks around 2 years of age, but may be attenuated by red blood cell transfusion.

Yoshiko Tamai, Hitoshi Ohto, Hiroyasu Yasuda, Akihiro Takeshita, Nobuharu Fujii, Hiroaki Ogo, Yurika Yazawa, Takaaki Hato, Kinuko Mitani, Keijiro Suzuki and 9 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Erythrocyte Alloimmunization and Autoimmunization in the Pediatric Population: A Multicenter, Cross-Sectional Study in Central China.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Yoshiko TamaiJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Hitoshi OhtoJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.ORCID 0000-0003-0340-883X
Hiroyasu YasudaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Akihiro TakeshitaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.ORCID 0000-0001-7504-6677
Nobuharu FujiiJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Hiroaki OgoJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Yurika YazawaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Takaaki HatoJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Kinuko MitaniJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Keijiro SuzukiJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Akihiko YokohamaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.ORCID 0000-0001-8514-086X
Yoko KatoJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Misao AbeJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Midori KumagawaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Yasunori UedaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Kenneth E NolletJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Laura CoolingDepartment of Pathology, The University of Michigan, Ann Arbor, Michigan, USA.
Junichi KitazawaJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Pediatric RBC Alloimmunization ConsortiumJapan Society of Blood Transfusion and Cell Therapy, Tokyo, Japan.
Japanese Red Cross Society, Japan · JPFukushima Medical University · JPHamamatsu University · JPHirosaki University · JPIwate Medical University · JPKansai Medical University · JPUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-M is frequently observed as a naturally occurring antibody of little clinical significance. Naturally occurring anti-M is often found in children although the specific triggers of production, persistence, and evanescence of anti-M have yet to be elucidated.

methodsIn a retrospective, multicenter, nationwide cohort survey conducted from 2001 to 2015, alloantibody screening was performed before and after transfusion in 18,944 recipients younger than 20 years. Recipients were categorized into six cohorts based on their age at transfusion; within and among these cohorts, allo-anti-M was analyzed in regard to its production, persistence, and evanescence.

resultsIn 44 patients, anti-M detected before and/or after transfusion was an age-related phenomenon, with a median age of 2 years and an interquartile range of 1-3 years; anti-M was most frequently detected in a cohort of children 1 to <5 years (0.77%, 31 of 4035). At least five patients were presumed to have concurrent infections. Among 1575 adolescents/young adults (15 to <20 years), no anti-M was detected. Of 29 patients with anti-M prior to transfusion, the antibody fell to undetectable levels in 17 recipients (89.5%, of whom at least 13 received only M-negative red cells) after anywhere from 5 days to 5.8 years; anti-M persisted in 2, and was not tested in 10. Only 15 recipients (0.08%) produced new anti-M after transfusion.

conclusionNaturally occurring anti-M is a phenomenon of younger ages, predominantly between 1 and 3 years. After transfusion, it often falls to undetectable levels.

Indexed as

Erythrocyte TransfusionChild, PreschoolFemaleHumansInfantIsoantibodiesMaleMNSs Blood-Group SystemRetrospective StudiesIsoantibodiesMNSs Blood-Group Systemanti-Mchildinfectionnaturally occurring antibody

Identifiers

PMID34287925
PMCPMC8518975
OpenAlexW3185814263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.